Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

121.86 -1.49 (-1.21%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 807,317
Open 123.44
Bid (Size) 121.49 (1)
Ask (Size) 122.42 (1)
Prev. Close 123.35
Today's Range 121.73 - 124.07
52wk Range 121.73 - 158.34
Shares Outstanding 122,180,759
Dividend Yield 1.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
Exposures COVID-19
Making Connections To Care: Quest Supports Inspiring Health Equity Event Hosted by Sisters on the Vineyard
Via ACCESSWIRE

Performance

YTD
-21.77%
-21.77%
1 Month
-9.52%
-9.52%
3 Month
-13.30%
-13.30%
6 Month
-13.87%
-13.87%
1 Year
-2.21%
-2.21%

More News

Read More
3 Pharma Stocks to Buy as Summer COVID Cases Spike
Via InvestorPlace
Exposures COVID-19
Why Bionano Genomics Stock Tanked Today
Via The Motley Fool
Quest Diagnostics: Dividend Insights
Via Benzinga
Analyst Ratings for Quest Diagnostics
Via Benzinga
The Latest Analyst Ratings for Quest Diagnostics
Via Benzinga
Will Chart Analysts Notice Bad Omen on Quest Diagnostics's Chart
Via Benzinga
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Via The Motley Fool
Looking for a Bargain? 3 Stocks to Buy That Are Down 10% in 2023
Via InvestorPlace
Quest Diagnostics Stock Falls on Lower Q2 Revenue and Profits from Lower Productivity Effects, Tightened Outlook
Via Benzinga
Sustaining Growth Momentum: Quest Diagnostics Continues to Excel and Reports Rising Profits
Via Benzinga
Quest Diagnostics, Keysight Technologies And A Stock Up 42% Year To Date On CNBC's 'Final Trades'
Via Benzinga
Quest Diagnostics Q1 Earnings Surpass Expectations; COVID-19 Testing Revenues Slump 80%
Via Benzinga
Analyst Expectations for Quest Diagnostics's Future
Via Benzinga
Biden Administration Releases Revised Guidance For Medicare Drug Price Negotiation Amid Industry Lawsuits
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Via Benzinga
FDA Readies Proposal for Increased Oversight on Lab-developed Tests
Via Benzinga
Want Growing Passive Income? Consider Buying This Stock
Via The Motley Fool
Post-Accident Workforce Drug Positivity For Marijuana Reached 25-Year High In 2022, Quest Diagnostics Drug Testing Index Analysis Finds
Via Benzinga
Exact Sciences Serves Investors Exactly What They Wished For
Via MarketBeat
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023
Via Benzinga
UiPath is a Cheaper and More Profitable AI Stock
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.